Community feedback highlights the importance of CF care teams, in-person CF care, and telehealth.
Revised approach to lung function reporting is shown to be more scientifically accurate and may reduce health disparities.
This year’s program marked the largest in-person advocacy event in the Foundation’s history.
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
A transformative leader for more than two decades, Marshall will transition to advisory role
The Foundation is committed to improving health outcomes for people with cystic fibrosis from underrepresented groups by supporting research projects advancing our understanding of barriers to health equity.
The Cystic Fibrosis Foundation mourns the passing of long-standing CF community champion and philanthropic leader who helped to raise more than $500 million toward the CF cause.
Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.